Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Choose a Ratio that Works for You: The best ratio is the one that simplifies your research protocol
Reconstitute at your destination when you have access to refrigeration again
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Trouble Focusing Support brain function, focus, and mental clarity
US$ 23.33
US$ 25.07
US$ 26.20
US$ 26.28
US$ 28.43
